|
|
 |
|
Viewing report
|
|
|
|
New Drug Futures 2009
Espicom Business Intelligence Ltd, April 2009, Pages: 450
The search - and need - for new products has never been greater and what’s in the development pipeline has never generated more interest.
MAJOR THERAPY AREAS ANALYSED
Anti-infectives
Cardiovascular
CNS
Gastrointestinal
Metabolic
Musculoskeletal
Oncology
Respiratory This 450-page report evaluates, compares and contrasts the prospects for the development compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond. That is why this analysis is so important!
The report provides:
Detailed background and market context for each therapy area covered:
- Addressable patient population
- Current treatments
- Sales drivers
- Sales breakers
- Future treatments
- Market dynamics - winners and losers
- Key drug launches by 2013
Unique sales forecasts by major product to 2013
Over 70 key products assessed
Unique evaluation scores for key areas such as novelty of mechanism, clinical data and competition
Critical and detailed appraisal of each product’s research and development
THE GLOBAL PHARMA MARKET IN CONTEXT
Too few novel products and an aggressive generic sector are taking their toll ... Are there too many prophets of doom ready to write-off the research-based pharma industry in the future?
There is plenty on which to base such anxiety. The research-based industry must achieve a fair price in the face of greater cost control, while the burden of regulation is setting the bar high for successful product introduction. Meanwhile, the generics sector is eating away at ageing and established portfolios.
It is a fair assessment to say that the industry has rested too much on its laurels and successful product portfolios. For too many years, too few novel medicines have been brought to market, laying the foundations for the industry’s current ills.
Can it be different?
The increasing number of biologicals that are coming to market have real potential for clinical and commercial progress, and while there is an innovation gap until new biological products make their market presence felt, there are considerable reasons to view the future more positively. A considered evaluation of the research pipeline shows that the future can be brighter than many pundits predict.
Essential analysis of 110 products that could change the face of the market
Over 70 winning drugs have been identified that could be launched by 2013. Products come from over 35 companies, ranging from multinationals and specialty pharma, to biopharmaceuticals and biotechnology companies.
Will they make it?
Our estimates assume products will gain approval for the indications we have forecast in the timeframe analysed. However, regulatory demands and pressures on cost and development budgets increasingly mean safe and effective medicines are not brought to market. That is why we provide a unique analysis of each product, examining its novelty of mechanism, clinical data, competitive environment, the experience of the developer and risks associated with development within that therapeutic class.
This report is essential reading for industry planners and investors
Anyone wanting an insightful analysis of the products and companies that will shape the global pharmaceutical industry over the next 5 years need look no further than this report.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
